| GR00016-A |
26524 |
26524 |
LATS2 |
np |
1.36 |
none |
|
no |
|
Wnt/beta-catenin pathway regulation |
Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. |
James et al. |
2009 |
19471023 |
Cell line |
RKO |
Wnt/beta-catenin pathway reporter |
Luminescence |
rp |
Selected genes |
siRNA |
Z-score |
> 2 |
|
GR00053-A |
26524 |
NM_014572 |
LATS2 |
np |
sp |
none |
|
no |
|
Genome stability |
A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. |
Paulsen et al. |
2009 |
19647519 |
Cell line |
HeLa |
gamma-H2AX phosphorylation and DNA content |
Fluorescence |
siARRAY human genome siRNA library |
Genome-wide |
siRNA |
p-value |
Complex criteria |
Confidence groupings from 4 to 1 (highest level of confidence in group 4) |
GR00054-A |
26524 |
NM_014572 |
LATS2 |
np |
0.962 |
none |
|
no |
|
Combinatorial effect with paclitaxel |
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. |
Whitehurst et al. |
2007 |
17429401 |
Cell line |
NCI-H1155 |
Viability (synthetic lethal) |
ATP level |
# G-005000-01 |
Genome-wide |
siRNA |
Paclitaxel/control ratio |
Complex criteria |
Additional information about 87 high-confidence hits |
|
26524 |
26524 |
LATS2 |
np |
np |
none |
|
no |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00056-A |
26524 |
NM_014572 |
LATS2 |
np |
1.059 |
none |
|
no |
|
Melanogenesis |
Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. |
Ganesan et al. |
2008 |
19057677 |
Cell line |
MNT-1 |
Melanin protein expression and viability |
Absorbance and luminescence |
rp |
Genome-wide |
siRNA |
Normalized absorbance ratio |
> 2 standard deviations below mean |
Additional information about a secondary screen (retest to determine false-positive rate) |
GR00057-A-1 |
26524 |
NM_014572 |
LATS2 |
M-003865-00 |
-0.82 |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (1) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Z-score |
> 4 |
Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00057-A-2 |
26524 |
NM_014572 |
LATS2 |
M-003865-00 |
sp |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (2) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Complex, SP |
Complex criteria |
Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00093-A-0 |
26524 |
|
LATS2 |
np |
2.2 |
Increased apoptosis |
|
no |
|
Apoptosis pathway |
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. |
MacKeigan et al. |
2005 |
15864305 |
Cell line |
HeLa |
Apoptosis (histone-DNA fragmentation) |
ELISA |
Custom-made library (Qiagen) |
|
siRNA |
Fold increase |
> |
|
GR00095-A |
26524 |
NM_014572 |
LATS2 |
np |
np |
none |
|
|
|
p53 pathway components |
A large-scale RNAi screen in human cells identifies new components of the p53 pathway |
Berns et al. |
2004 |
15042092 |
Cell line |
BJ-TERT-tsLT fibroblasts |
Proliferation |
Colony-forming cell assay |
Nki library |
Genome-wide |
shRNA |
np |
np |
|
GR00098-A-1 |
26524 |
ENSG00000150457 |
LATS2 |
ENSG00000150457 |
sp |
none |
|
no |
|
Cell division (1) |
Genome-scale RNAi profiling of cell division in human tissue culture cells. |
Kittler et al. |
2007 |
17994010 |
Cell line |
HeLa |
Cell number and DNA content |
Laser scanning cytometry |
rp |
Genome-wide |
esiRNA |
Complex, sp |
Complex criteria |
|
GR00100-A |
26524 |
NM_014572 |
|
v2HS_86041 |
np |
none |
|
|
|
Mitosis regulation |
Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. |
Stegmeier et al. |
2007 |
17443180 |
Cell line |
HeLa |
Cell cycle |
Microscopy |
np |
Selected genes |
shRNA |
Mitotic index |
np |
Sequences are avaible. |
GR00114-A |
26524 |
|
LATS2 |
np |
1.34 |
none |
|
|
108% |
Combinatorial effect with Poly (ADPâ€ribose)â€polymeraseâ€1 (PARP) |
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. |
Turner et al. |
2008 |
18388863 |
Cell line |
CAL51 |
Viability |
Luminescence |
siARRAY SMARTpool |
Kinases |
siRNA |
Z-score |
< |
Growth rates (%) for vehicle-alone experiments are given in the comment field. |
GR00121-A |
26524 |
|
LATS2 |
TRCN0000000883 |
4.28 |
none |
|
|
hit in RCC4 screen |
Combinatorial effect with Von Hippel-Lindau (VHL) |
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. |
Bommi-Reddy et al. |
2008 |
18948595 |
Cell line |
786-O |
Viability |
Colorimetric |
lentiviral library |
Kinases |
shRNA |
Differential loss of viability (%) |
> |
Additional screen in RCC4 cells available |
GR00123-A |
26524 |
NM_014572 |
LATS2 |
103551, 103553, 103552 |
np |
none |
|
|
|
Combinatorial effect with nutlin-3 |
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors |
Brummelkamp et al. |
2006 |
16474381 |
Cell line |
MCF-7 |
Viability |
Fluoresence |
Nki library |
Genome-wide |
shRNA |
log2 ratio |
np |
|
GR00133-A-1 |
26524 |
26524 |
LATS2 |
np |
0.3127 |
none |
|
no |
|
Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) |
RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. |
Misselwitz et al. |
2011 |
21407211 |
Cell line |
HeLa |
Gentamycin protection invasion assay |
Fluorescence |
Druggable genome library V2.0 |
Druggable genes |
siRNA |
log2 median |
Complex criteria |
|
GR00143-A |
26524 |
|
LATS2 |
LATS2 s1 |
sp |
none |
|
no |
|
tau phosphorylation |
High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. |
Azorsa et al. |
2010 |
20067632 |
Cell line |
H4 overexpressing 4RON tau |
Total tau and 12E8 tau protein expression |
Fluorescence |
Validated human kinase siRNA Set 2.0 |
Kinases |
siRNA |
p-value |
Complex criteria |
|
GR00143-A |
26524 |
|
LATS2 |
LATS2 s2 |
sp |
none |
|
no |
|
tau phosphorylation |
High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. |
Azorsa et al. |
2010 |
20067632 |
Cell line |
H4 overexpressing 4RON tau |
Total tau and 12E8 tau protein expression |
Fluorescence |
Validated human kinase siRNA Set 2.0 |
Kinases |
siRNA |
p-value |
Complex criteria |
|
GR00149-A-1 |
26524 |
26524 |
LATS2 |
948 |
32.39 |
none |
|
no |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
26524 |
26524 |
LATS2 |
948 |
-9.36 |
none |
|
no |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
26524 |
26524 |
LATS2 |
949 |
29.46 |
none |
|
no |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
26524 |
26524 |
LATS2 |
949 |
25.8 |
none |
|
no |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
26524 |
26524 |
LATS2 |
134431 |
-23.27 |
none |
|
no |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
26524 |
26524 |
LATS2 |
134431 |
21.64 |
none |
|
no |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00151-A-1 |
26524 |
ENSG00000150457 |
LATS2 |
np |
-0.137 |
none |
|
no |
|
Homologous recombination DNA double-strand break repair (HR-DSBR) (1) |
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. |
Słabicki et al. |
2010 |
20613862 |
Cell line |
HeLa |
(HR-DSBR) DR-GFP reporter |
Flow cytometry |
Custom-made |
Genome-wide |
esiRNA |
Z-score |
< -2 OR > 2 |
|
GR00155-A |
26524 |
26524 |
LATS2 |
LATS2_1, LATS2_2, LATS2_3 |
np |
none |
|
no |
|
Aryl hydrocarbon receptor (AhR) transduction pathway regulation |
RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity. |
Gilot et al. |
2011 |
21479225 |
Cell line |
MCF-7 |
TCDD-induced CYP1A1-related EROD activity and cell viability |
Fluorescence and methylene blue |
MISSION siRNA Human Kinase Panel library |
Kinases |
siRNA |
Z-score |
Top 150 for > |
|
GR00180-A-1 |
26524 |
26524 |
LATS2 |
PL-50002 |
0.915 |
none |
|
no |
|
Hepatitis C virus replication (1) |
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. |
Tai et al. |
2009 |
19286138 |
Cell line |
Huh7/Rep-Feo |
HCV replicon RNA copy number |
Luminescence |
siARRAY Human Genome siRNA Library |
Genome-wide |
siRNA |
q-value |
Complex criteria |
|
GR00184-A-1 |
26524 |
NM_014572 |
LATS2 |
M-003865-00 |
0.618393162862979 |
none |
|
no |
|
Self-renewal and pluripotency in human embryonic stem cells (1) |
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. |
Chia et al. |
2010 |
20953172 |
Cell line |
hESC H1 |
POU5F1 protein expression |
Fluorescence |
SMARTpool siRNA library |
Genome-wide |
siRNA |
Z-score |
< -2 |
|
GR00193-A-1 |
26524 |
26524 |
LATS2 |
LATS2 |
0.967387264702452 |
none |
|
yes |
Illumina gene expression above basal level (p < 0.05) |
Therapeutic kinase targets in neuroblastoma (1) |
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. |
Cole et al. |
2011 |
21289283 |
Cell line |
EBC1 |
Substrate adherent cell growth |
rp |
Kinase siGenome library |
Kinases |
siRNA |
Relative growth |
0.5 standard deviations below mean |
|
GR00193-A-2 |
26524 |
26524 |
LATS2 |
LATS2 |
0.851953170890765 |
none |
|
yes |
|
Therapeutic kinase targets in neuroblastoma (2) |
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. |
Cole et al. |
2011 |
21289283 |
Cell line |
KELLY |
Substrate adherent cell growth |
rp |
Kinase siGenome library |
Kinases |
siRNA |
Relative growth |
0.5 standard deviations below mean |
|
GR00193-A-3 |
26524 |
26524 |
LATS2 |
LATS2 |
1.04649381437744 |
none |
|
yes |
|
Therapeutic kinase targets in neuroblastoma (3) |
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. |
Cole et al. |
2011 |
21289283 |
Cell line |
SKNAS |
Substrate adherent cell growth |
rp |
Kinase siGenome library |
Kinases |
siRNA |
Relative growth |
0.5 standard deviations below mean |
|
GR00193-A-4 |
26524 |
26524 |
LATS2 |
LATS2 |
0.694320765238279 |
none |
|
no |
Illumina gene expression above basal level (p < 0.05) |
Therapeutic kinase targets in neuroblastoma (4) |
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. |
Cole et al. |
2011 |
21289283 |
Cell line |
NLF |
Substrate adherent cell growth |
rp |
Kinase siGenome library |
Kinases |
siRNA |
Relative growth |
0.5 standard deviations below mean |
|
GR00196-A-1 |
26524 |
ENSG00000150457 |
|
np |
sp |
none |
|
no |
|
TP53 interactions (1) |
A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. |
Krastev et al. |
2011 |
21642980 |
Cell line |
HCT116 ( wildtype and TP53 knockout) |
TP53 protein expression and viability |
Fluorescence |
rp |
Genome-wide |
esiRNA |
Complex, sp |
Complex criteria |
|
GR00197-A-1 |
26524 |
26524 |
LATS2 |
M-003865-00 |
0.766908908 |
none |
|
no |
|
Human papillomavirus oncogene expression regulation (1) |
Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. |
Smith et al. |
2010 |
20133580 |
Cell line |
C33A/BE2/18LCR c4 |
HPV18 LCR reporter activity |
Luminescence |
Human siGENOME SMARTpool library |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 |
GR00210-A |
26524 |
26524 |
LATS2 |
np |
sp |
none |
|
no |
|
Focal adhesion formation |
Multiparametric analysis of focal adhesion formation by RNAi-mediated gene knockdown. |
Winograd-Katz et al. |
2009 |
19667130 |
Cell line |
HeLa |
paxillin protein expression |
Fluorescence |
SMARTpool siARRAY siRNA Libraries |
Kinases, phosphatases and selected genes |
siRNA |
Z-score |
> 3.5 OR < -3.5 |
|
GR00211-A |
26524 |
NM_014572 |
LATS2 |
3443 |
4 |
Increased ID2::GFP protein expression |
|
no |
|
Inhibitor of DNA binding 2 (ID2) expression regulation |
Large scale RNAi screen reveals that the inhibitor of DNA binding 2 (ID2) protein is repressed by p53 family member p63 and functions in human keratinocyte differentiation. |
Wu et al. |
2011 |
21478550 |
Cell line |
HaCaT |
ID2::GFP protein expression |
Fluorescence |
Human Cancer siRNA Set v2 |
Selected genes |
siRNA |
GFP ratio medians ranking |
Top 6 for > |
|
GR00221-A-1 |
26524 |
|
LATS2 |
TRCN0000000883 |
-1.26 |
Decreased viability |
|
yes |
|
Proliferation of cells with active beta-catenin (1) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MCF-7 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-1 |
26524 |
|
LATS2 |
TRCN0000000881 |
-0.81 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (1) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MCF-7 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-1 |
26524 |
|
LATS2 |
TRCN0000000884 |
0.31 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (1) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MCF-7 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-1 |
26524 |
|
LATS2 |
TRCN0000000882 |
0.58 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (1) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MCF-7 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-1 |
26524 |
|
LATS2 |
TRCN0000000880 |
1.11 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (1) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MCF-7 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-2 |
26524 |
|
LATS2 |
TRCN0000000883 |
-2.13 |
Decreased viability |
|
yes |
|
Proliferation of cells with active beta-catenin (2) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-231 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-2 |
26524 |
|
LATS2 |
TRCN0000000880 |
-0.3 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (2) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-231 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-2 |
26524 |
|
LATS2 |
TRCN0000000881 |
0.72 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (2) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-231 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-2 |
26524 |
|
LATS2 |
TRCN0000000884 |
1.09 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (2) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-231 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-2 |
26524 |
|
LATS2 |
TRCN0000000882 |
1.41 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (2) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-231 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-3 |
26524 |
|
LATS2 |
TRCN0000000881 |
-0.81 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (3) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-453 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-3 |
26524 |
|
LATS2 |
TRCN0000000882 |
-0.42 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (3) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-453 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-3 |
26524 |
|
LATS2 |
TRCN0000000880 |
-0.32 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (3) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-453 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-3 |
26524 |
|
LATS2 |
TRCN0000000883 |
0.17 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (3) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-453 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-3 |
26524 |
|
LATS2 |
TRCN0000000884 |
1.68 |
none |
|
yes |
|
Proliferation of cells with active beta-catenin (3) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
MDA-MB-453 |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-4 |
26524 |
|
LATS2 |
TRCN0000000881 |
-1.25 |
Decreased viability |
|
no |
|
Proliferation of cells with active beta-catenin (4) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
T47D |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-4 |
26524 |
|
LATS2 |
TRCN0000000882 |
-0.6 |
none |
|
no |
|
Proliferation of cells with active beta-catenin (4) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
T47D |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-4 |
26524 |
|
LATS2 |
TRCN0000000884 |
0.2 |
none |
|
no |
|
Proliferation of cells with active beta-catenin (4) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
T47D |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-4 |
26524 |
|
LATS2 |
TRCN0000000883 |
0.51 |
none |
|
no |
|
Proliferation of cells with active beta-catenin (4) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
T47D |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00221-A-4 |
26524 |
|
LATS2 |
TRCN0000000880 |
0.79 |
none |
|
no |
|
Proliferation of cells with active beta-catenin (4) |
CK1epsilon is required for breast cancers dependent on beta-catenin activity. |
Kim et al. |
2010 |
20126544 |
Cell line |
T47D |
Viability |
Luminescence |
TRC shRNA Library |
Kinases |
shRNA |
B-score |
< -1 |
Essential gene: gene with B-score < -1 for > |
GR00225-A |
26524 |
|
LATS2 |
LATS2_A |
-0.118785 |
none |
10nM gemcitabine |
no |
|
Combinatorial effect with gemcitabine |
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. |
Azorsa et al. |
2009 |
19519883 |
Cell line |
MIAPaCa-2 |
Viability (synthetic lethal) |
Luminescence |
Validated kinase siRNA library version 1.0 |
Kinases |
siRNA |
log2 ratio |
1.65 SD below mean ratio level |
|
GR00225-A |
26524 |
|
LATS2 |
LATS2_B |
-0.516199 |
none |
10nM gemcitabine |
no |
|
Combinatorial effect with gemcitabine |
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. |
Azorsa et al. |
2009 |
19519883 |
Cell line |
MIAPaCa-2 |
Viability (synthetic lethal) |
Luminescence |
Validated kinase siRNA library version 1.0 |
Kinases |
siRNA |
log2 ratio |
1.65 SD below mean ratio level |
|
GR00225-A |
26524 |
|
LATS2 |
LATS2_A |
-0.185478 |
none |
5nM gemcitabine |
no |
|
Combinatorial effect with gemcitabine |
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. |
Azorsa et al. |
2009 |
19519883 |
Cell line |
MIAPaCa-2 |
Viability (synthetic lethal) |
Luminescence |
Validated kinase siRNA library version 1.0 |
Kinases |
siRNA |
log2 ratio |
1.65 SD below mean ratio level |
|
GR00225-A |
26524 |
|
LATS2 |
LATS2_B |
-0.269887 |
none |
5nM gemcitabine |
no |
|
Combinatorial effect with gemcitabine |
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. |
Azorsa et al. |
2009 |
19519883 |
Cell line |
MIAPaCa-2 |
Viability (synthetic lethal) |
Luminescence |
Validated kinase siRNA library version 1.0 |
Kinases |
siRNA |
log2 ratio |
1.65 SD below mean ratio level |
|
|
26524 |
NM_014572 |
LATS2 |
np |
2.104349 |
Decreased viability after TNF/CHX stimulation |
|
no |
99% confidence interval |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00230-A-2 |
26524 |
|
LATS2 |
np |
strong |
Decreased senescence-associated beta-galactosidase protein expression after pRB stimulation |
|
yes |
|
pRB-induced cell cycle regulation (2) |
A kinase shRNA screen links LATS2 and the pRB tumor suppressor. |
Tschöp et al. |
2011 |
21498571 |
Cell line |
SaOS2-TR-pRB |
Senescence-associated beta-galactosidase protein expression |
Colorimetrics |
Lentiviral shRNA library |
Kinases |
shRNA |
Intensity and percentage of stained cells |
Strong for > |
|
GR00231-A |
26524 |
NM_014572 |
LATS2 |
M-003865-00 |
0.966 |
none |
|
yes |
|
Cell proliferation |
Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. |
Zhang et al. |
2011 |
21765947 |
Cell line |
HeLa |
Viability |
Electrical impedance |
Human siARRAY - Protein Kinase and Cell Cycle libraries |
Kinases and selected genes |
siRNA |
Z-score |
< -1.96 OR > 1.96 |
Additional information about cell titer blue cell viability screen |
GR00234-A-1 |
26524 |
NM_014572 |
LATS2 |
np |
sp |
none |
|
no |
|
Hepatitis C virus (HCV) infection (1) |
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. |
Lupberger et al. |
2011 |
21516087 |
Cell line |
Huh7 |
Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) protein expression |
Luminescence |
Human Kinase RNAi Set V2.0 |
Kinases |
siRNA |
Complex, sp |
Complex criteria |
|
|
26524 |
|
LATS2 |
np |
np |
Decreased viability in glioblastoma multiforme (GBM) lineage |
|
no |
GBM: no filter, KS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00236-A-1 |
26524 |
26524 |
LATS2 |
M-003865-00 |
1.14387484841372 |
none |
|
no |
|
Homologous recombination DNA double-strand break repair (HR-DSBR) (1) |
A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. |
Adamson et al. |
2012 |
22344029 |
Cell line |
DR-U2OS |
(HR-DSBR) DR-GFP reporter and DNA content |
Fluorescence |
Human siGENOME siRNA (G-005000-05) |
Genome-wide |
siRNA |
Relative HR ratio |
< ~0.4 OR > 1.88 |
Cutoff values correspond 2 standard deviations from the screen-wide mean |
GR00240-S-1 |
26524 |
NM_014572 |
LATS2 |
M-003865-00 |
-1.05 |
none |
|
yes |
|
TRAIL-induced apoptosis (1) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Z-score |
> 4 |
Author-submitted data |
GR00240-S-2 |
26524 |
NM_014572 |
LATS2 |
M-003865-00 |
2.15 |
none |
|
no |
Z-score 1.342 |
TRAIL-induced apoptosis (2) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability (synthetic lethal) |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Differential score |
> 3.6 AND viability Z-score < 4 |
Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. |
GR00242-A-1 |
26524 |
NM_014572 |
LATS2 |
np |
sp |
none |
|
no |
|
Selective autophagy regulation (1) |
Image-based genome-wide siRNA screen identifies selective autophagy factors. |
Orvedahl et al. |
2011 |
22020285 |
Cell line |
HeLa/GFP-LC3 |
Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression |
Fluorescence |
siGenome |
Genome-wide |
siRNA |
Z-score |
Complex criteria |
|
GR00247-A-1 |
26524 |
|
LATS2 |
np |
sp |
none |
|
|
rank: 17060 |
Regulation of FOXO1 nuclear localization (1) |
Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. |
Senapedis et al. |
2011 |
21460183 |
Cell line |
U2OS |
EGFP-FOXO1a protein expression and DNA content |
Fluorescence |
Human Genome library |
Genome-wide |
siRNA |
Complex, sp |
Complex criteria |
|
GR00248-A |
26524 |
NM_014572 |
LATS2 |
LATS2_siRNA1 |
-0.613 |
none |
|
|
|
Human cytomegalovirus (HCMV) strain AD169 replication |
Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. |
Terry et al. |
2012 |
22315427 |
Cell line |
MRC5 |
Human cytomegalovirus (HCMV) IE1 protein expression |
Fluorescence |
Mission siRNA Human Kinase Panel |
Kinases |
siRNA |
Z-score |
> |
|
GR00248-A |
26524 |
NM_014572 |
LATS2 |
LATS2_siRNA2 |
-0.356 |
none |
|
|
|
Human cytomegalovirus (HCMV) strain AD169 replication |
Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. |
Terry et al. |
2012 |
22315427 |
Cell line |
MRC5 |
Human cytomegalovirus (HCMV) IE1 protein expression |
Fluorescence |
Mission siRNA Human Kinase Panel |
Kinases |
siRNA |
Z-score |
> |
|
GR00248-A |
26524 |
NM_014572 |
LATS2 |
LATS2_siRNA3 |
0.51 |
none |
|
|
|
Human cytomegalovirus (HCMV) strain AD169 replication |
Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. |
Terry et al. |
2012 |
22315427 |
Cell line |
MRC5 |
Human cytomegalovirus (HCMV) IE1 protein expression |
Fluorescence |
Mission siRNA Human Kinase Panel |
Kinases |
siRNA |
Z-score |
> |
|
GR00249-S |
26524 |
26524 |
LATS2 |
J-003865-09 |
-0.90417 |
none |
|
no |
number of cells compared to control (%): 77.42 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
26524 |
26524 |
LATS2 |
M-003865-02 |
3.33027 |
Increased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 79.10 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
26524 |
26524 |
LATS2 |
s25503 |
1.36099 |
Increased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 81.71 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
26524 |
26524 |
LATS2 |
s25504 |
0.02529 |
none |
|
no |
number of cells compared to control (%): 89.95 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
26524 |
26524 |
LATS2 |
s25505 |
-0.11594 |
none |
|
no |
number of cells compared to control (%): 83.13 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00253-A |
26524 |
NM_014572 |
LATS2 |
np |
0.535 |
none |
|
|
|
hepcidin regulation |
Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. |
Mleczko-Sanecka et al. |
2014 |
24385536 |
Cell line |
Huh7 |
hepcidin::fluc mRNA expression |
Luminescence |
siGenome siARRAY SMARTpool |
Genome-wide |
siRNA |
Z-score |
> |
Cutoff < |
GR00255-A-1 |
26524 |
26524 |
LATS2 |
TRCN0000000880, TRCN0000000881, TRCN0000000882, TRCN0000000883, TRCN0000000884 |
-0.202303172 |
none |
|
|
|
Negative genetic interactions (1) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-2 |
26524 |
26524 |
LATS2 |
TRCN0000000880, TRCN0000000881, TRCN0000000882, TRCN0000000883, TRCN0000000884 |
-0.371123954 |
none |
|
|
|
Negative genetic interactions (2) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-3 |
26524 |
26524 |
LATS2 |
TRCN0000000880, TRCN0000000881, TRCN0000000882, TRCN0000000883, TRCN0000000884 |
-0.071539803 |
none |
|
|
|
Negative genetic interactions (3) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-4 |
26524 |
26524 |
LATS2 |
TRCN0000000880, TRCN0000000881, TRCN0000000882, TRCN0000000883, TRCN0000000884 |
0.226165619 |
none |
|
|
|
Negative genetic interactions (4) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-5 |
26524 |
26524 |
LATS2 |
TRCN0000000880, TRCN0000000881, TRCN0000000882, TRCN0000000883, TRCN0000000884 |
0.183812984 |
none |
|
|
|
Negative genetic interactions (5) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -0.8 |
HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00256-A |
26524 |
NM_014572 |
LATS1 |
np |
sp |
none |
|
|
|
Kinase-mediated spindle orientation |
ABL1 regulates spindle orientation in adherent cells and mammalian skin. |
Matsumara et al. |
2012 |
22252550 |
Cell line |
HeLa |
beta-tubulin protein expression and DNA content |
Fluorescence |
Silencer Kinase siRNA library (AM80010V3) |
Kinases |
siRNA |
Complex, sp |
Complex criteria |
HeLa cells stably expressing GFP-H2B (HeLa-GH2B) used. Additional information about secondary screens. |
GR00257-A-1 |
26524 |
|
lats2 |
950 |
sp |
Decreased viability (cell death), increased nuclear migration distance |
|
|
|
Cell division, migration and survival (1) |
Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. |
Neumann et al. |
2010 |
20360735 |
Cell line |
HeLa |
H2B-GFP protein expression |
Fluorescence |
Mapped using ENSEMBL genome database version 27 |
Selected genes |
siRNA |
Complex, sp |
Complex criteria |
HeLa-H2B-GFP cells used. |
GR00293-A |
26524 |
|
LATS2 |
np |
0.686 |
none |
|
|
|
Combinatorial effect with paclitaxel |
Mechanisms Promoting Escape from Mitotic Stress−Induced Tumor Cell Death |
Sinnott et al. |
2014 |
24860162 |
Cell line |
HCC366 |
Viability |
Luminescence |
Thermo-Fisher |
Genome-wide |
siRNA |
Z-score |
< -2.5 |
Final hits according to the author are indicated in the comment. |
GR00300-A |
26524 |
|
LATS2 |
TRCN0000000880, TRCN0000000882, TRCN0000000881, TRCN0000000884, TRCN0000199570, TRCN0000000883, TRCN0000195674, TRCN0000194755, TRCN0000197058 |
0 |
none |
|
|
|
Combinatorial effect with RAF inhibitor PLX4720 |
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. |
Whittaker et al. |
2013 |
23288408 |
Cell line |
A375 |
shRNA abundance |
Sequencing |
TRC |
Genome-wide |
shRNA |
Number of shRNAs ranked Top1000 |
> 2 |
The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. |
GR00303-A |
26524 |
NM_014572 |
LATS2 |
np |
-0.01 |
none |
|
|
|
Clear cell renal cell carcinoma (ccRCC) survival regulation |
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target |
Gerlinger et al. |
2012 |
22362593 |
Cell line |
VHL-deficient RCC4 |
Proliferation and Viability |
Fluorescence |
np |
Genome-wide |
siRNA |
Z-score |
< |
In the phenotype data duplicates were in the original document, which have been removed. |
GR00310-A-1 |
26524 |
26524 |
LATS2 |
np |
0.27 |
none |
|
|
|
Sindbis virus (SINV) infection (1) |
Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry |
Ooi et al. |
2013 |
24367265 |
Cell line |
U2OS |
Sindbis virus (SINV) reporter |
Luminescence |
Ambion Silencer V3 |
Genome-wide |
siRNA |
Z-score |
< -3 OR > 2 |
|
|
26524 |
26524 |
LATS2 |
np |
15 |
none |
|
|
124,2% viability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00313-A |
26524 |
NM_014572 |
LATS2 |
np |
-0.62 |
none |
|
|
|
TNF-alpha pathway regulation |
A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. |
Nickles et al. |
2012 |
22733992 |
Cell line |
HEK293T |
NFkappaB pathway reporter |
Luminescence |
Qiagen |
Genome-wide |
siRNA |
Z-score |
< |
Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. |
GR00318-A |
26524 |
26524 |
LATS2 |
np |
1.248 |
none |
|
|
siRNA set: kinase |
Huntingtin toxicity |
A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease |
Miller et al. |
2012 |
23209424 |
Cell line |
HEK293T |
Caspase 3/7 activity |
Fluorescence |
Dharmacon |
Selected genes |
siRNA |
Sum of normalized caspase 3/7 activity mean and standard error |
< 0.683 |
HEK293T cells were cotransfected with mutant Huntingtin fused to GFP (Htt1-558141Q-GFP). |
GR00342-S-1 |
26524 |
|
LATS2 |
M-003865-00 |
1.1591152596127832 |
none |
|
|
|
Viability of Mesenchymal Stem Cells (MSC) (1) |
Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening |
Erdmann et al. |
2015 |
26120366 |
Primary cells |
Bone marrow derived MSC |
Viability |
Luminescence |
Kinase siGENOME SMARTpool library |
Kinases and phosphatases |
siRNA |
Z-score |
> |
Donor 1, MSC preparation 1 (MSC1a) |
GR00342-S-2 |
26524 |
|
LATS2 |
M-003865-00 |
1.3672518811544072 |
none |
|
|
|
Viability of Mesenchymal Stem Cells (MSC) (2) |
Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening |
Erdmann et al. |
2015 |
26120366 |
Primary cells |
Bone marrow derived MSC |
Viability |
Luminescence |
Kinase siGENOME SMARTpool library |
Kinases and phosphatases |
siRNA |
Z-score |
> |
Donor 1, MSC preparation 2 (MSC1b) |
GR00342-S-3 |
26524 |
|
LATS2 |
M-003865-00 |
0.7351020358809442 |
none |
|
|
|
Viability of Mesenchymal Stem Cells (MSC) (3) |
Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening |
Erdmann et al. |
2015 |
26120366 |
Primary cells |
Bone marrow derived MSC |
Viability |
Luminescence |
Kinase siGENOME SMARTpool library |
Kinases and phosphatases |
siRNA |
Z-score |
> |
Donor 2, MSC preparation 1 (MSC2) |
GR00343-S |
26524 |
26524 |
LATS2 |
TRCN0000000883 |
0.3600000000000012 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
26524 |
26524 |
LATS2 |
TRCN0000000880 |
-0.005000000000000782 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
26524 |
26524 |
LATS2 |
TRCN0000000881 |
1.3575 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
26524 |
26524 |
LATS2 |
TRCN0000000882 |
-0.18499999999999872 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
26524 |
26524 |
LATS2 |
TRCN0000000884 |
1.0150000000000006 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00356-A-1 |
26524 |
NM_014572 |
LATS2 |
np |
0.53 |
none |
|
|
|
Clathrin-mediated endocytosis |
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. |
Pelkmans et al. |
2005 |
15889048 |
Cell line |
HeLa |
Vesicular stomatitis virus (VSV) infection (rVSV–GFP expression) |
Fluorescence |
Ambion |
Kinases |
siRNA |
Relative infection index (RII) |
< |
The cutoff was < 0.4 OR > 2.5 if the gene also scored in the additional screen "Caveolin- and lipid raft-mediated endocytosis" using simian virus 40 (SV40). |
GR00356-A-2 |
26524 |
NM_014572 |
LATS2 |
np |
0.7119839026183106 |
none |
|
|
|
Caveolin- and lipid raft-mediated endocytosis |
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. |
Pelkmans et al. |
2005 |
15889048 |
Cell line |
HeLa |
Simian virus 40 (SV40) infection (SV40 large T-antigen expression) |
Fluorescence |
Ambion |
Kinases |
siRNA |
Relative infection index (RII) |
< |
The cutoff was < 0.4 OR > 2.5 if the gene also scored in the additional screen "Clathrin-mediated endocytosis" using vesicular stomatitis virus (VSV). |
GR00356-A-3 |
26524 |
NM_014572 |
LATS2 |
np |
np |
none |
|
|
|
Endocytosis regulation |
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. |
Pelkmans et al. |
2005 |
15889048 |
Cell line |
HeLa |
Transferrin (Tfn) uptake and trafficking |
Fluorescence |
Ambion |
Kinases |
siRNA |
np |
np |
|
GR00363-A |
26524 |
26524 |
LATS2 |
SI02660161, esi9036, SI02660154, 950, SI02660385, SI02224516, 949, 948 |
sp |
Increased epidermal growth factor (EGF) endocytosis |
|
|
strong |
Endocytosis regulation |
Systems survey of endocytosis by multiparametric image analysis. |
Collinet et al. |
2010 |
20190736 |
Cell line |
HeLa |
Transferrin (TF) and epidermal growth factor (EGF) subcellular localisation, DNA content |
Fluorescence |
Ambion, Qiagen and esiRNA library (Kittler et al.) |
Genome-wide |
siRNA |
Complex, sp |
Complex criteria |
Two hit categories: "strong" (maximum of Prob Chi2, Prob Chi2 EGF, Prob Chi2 Tfn > 0.95) and "weak but specific" (maximum of Prob Chi2, Prob Chi2 EGF, Prob Chi2 Tfn < 0.95 but Phenoscore > 0.95). Additional information about secondary screens with kinase and phospatase libraries. |
|
26524 |
26524 |
LATS2 |
|
0.010000000000000002 |
none |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00371-A-1 |
26524 |
26524 |
LATS2 |
|
0.139463696007 |
none |
|
|
Dharmacon |
Nanog expression in absence of bFGF and TGFbeta |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-2 |
26524 |
LATS2 |
26524 |
|
0.0235627329149 |
none |
|
|
Dharmacon |
Nanog expression in presence of TGFbeta inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-3 |
26524 |
26524 |
LATS2 |
|
-0.170258878283 |
none |
|
|
Dharmacon |
Nanog expression in presence of MEK inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-4 |
26524 |
26524 |
LATS2 |
|
0.526601376388 |
none |
|
|
Dharmacon |
Nanog expression in presence of PI3K inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-5 |
26524 |
26524 |
LATS2 |
|
-0.212458145784 |
none |
|
|
Dharmacon |
Nanog expression in presence of retinoic acid |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00376-A-1 |
26524 |
26524 |
LATS2 |
|
0.03571637 |
none |
|
|
|
Mitigators of SS1P-induced immunotoxicity |
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity |
Pasetto et al. |
2015 |
25713356 |
Cell line |
KB cells |
Viability |
Luminescence |
Ambion Silencer Select Version 4 |
Genome-wide |
siRNA |
RSA P-value |
<0.001 |
SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID |
GR00376-A-2 |
26524 |
26524 |
LATS2 |
|
0.02394382 |
none |
|
|
|
Sensitizers of SS1P-induced immunotoxicity |
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity |
Pasetto et al. |
2015 |
25713356 |
Cell line |
KB cells |
Viability |
Luminescence |
Ambion Silencer Select Version 4 |
Genome-wide |
siRNA |
RSA P-value |
<0.001 |
SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID |
GR00378-A |
26524 |
|
LATS2 |
|
-0.241891099 |
none |
|
|
|
Poliovirus vaccine production |
Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game |
van der Sanden et al. |
2015 |
26581994 |
Cell line |
HEp-2C |
Infection with Attenuated Poliovirus |
ELISA |
Dharmacon |
Genome-wide |
siRNA |
Z-score |
> |
For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol |
|
26524 |
NM_014572 |
LATS2 |
|
53.235 |
none |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00386-A-1 |
26524 |
26524 |
LATS2 |
|
125.053655603397 |
Increased viability |
|
|
|
NOD2 stimulation by MDP |
A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. |
Warner et al. |
2014 |
25170077 |
Cell line |
HEK293 stably expressing NOD2 |
Viability |
Luminescence |
Dharmacon |
Genome-wide |
siRNA |
Percentage growth |
Decreased: <70, increased: >120 |
Reagent IDs not provided |
GR00386-A-2 |
26524 |
26524 |
LATS2 |
|
-131.6 |
none |
|
|
|
MDP-induced IL-8 secretion |
A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. |
Warner et al. |
2014 |
25170077 |
Cell line |
HEK293 stably expressing NOD2 |
IL-8 secretion |
ELISA |
Dharmacon |
Genome-wide |
siRNA |
Percent inhibition of IL-8 secretion |
Increased: <-300, Decreased: >60 |
Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |